BN Business News
Add your company to Business Communicator →

Business · 09/10/2026

European Medicines Agency Approves Modification to Paediatric Investigation Plan for Fabhalta and Iptacopan

The European Medicines Agency has made a decision on a modification to a Paediatric Investigation Plan (PIP) for Fabhalta and Iptacopan, a treatment for Renal and urinary disorders, following an application for change to the existing plan.

Source: EMA — Paediatric Investigation PlansOpen original release →